Revolution Medicines: FDA accelerates RASONQUE in first line – Morgan Stanley sees $12 billion peak revenue

The FDA grants Breakthrough Therapy designation for RASONQUE plus chemotherapy for the first-line treatment of metastatic pancreatic cancer. In the pivotal Phase III study, RASONQUE nearly doubled the median overall survival from 6.7 to 13.2 months and reduced the risk of death by 60%. Morgan Stanley views Revolution Medicines as a leading RAS oncology platform and models a risk-adjusted peak revenue of $12 billion by 2036. Revolution Medicines (RVMD) develops targeted cancer therapies for RAS-driven tumors and is trading close to its...